These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32629402)

  • 1. MSCOVID19: Using social media to achieve rapid dissemination of health information.
    Nesbitt C; Rath L; Yeh WZ; Zhong M; Wesselingh R; Monif M; Richards J; Minh VB; Jokubaitis VG; Skibina O; Butzkueven H; van der Walt A
    Mult Scler Relat Disord; 2020 Oct; 45():102338. PubMed ID: 32629402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
    Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
    Front Immunol; 2020; 11():1059. PubMed ID: 32477373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
    Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
    Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
    Mateen FJ; Rezaei S; Alakel N; Gazdag B; Kumar AR; Vogel A
    J Neurol; 2020 Dec; 267(12):3467-3475. PubMed ID: 32638107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
    De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
    Chiarini M; Paghera S; Moratto D; Rossi N; Giacomelli M; Badolato R; Capra R; Imberti L
    J Neuroimmunol; 2020 Aug; 345():577282. PubMed ID: 32505908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
    Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
    Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal and Location Variations, and Link Categories for the Dissemination of COVID-19-Related Information on Twitter During the SARS-CoV-2 Outbreak in Europe: Infoveillance Study.
    Pobiruchin M; Zowalla R; Wiesner M
    J Med Internet Res; 2020 Aug; 22(8):e19629. PubMed ID: 32790641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
    Maghzi AH; Houtchens MK; Preziosa P; Ionete C; Beretich BD; Stankiewicz JM; Tauhid S; Cabot A; Berriosmorales I; Schwartz THW; Sloane JA; Freedman MS; Filippi M; Weiner HL; Bakshi R
    J Neurol; 2020 Oct; 267(10):2790-2796. PubMed ID: 32494856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.
    Racke MK; Newsome SD
    J Neuroimmunol; 2020 Aug; 345():577283. PubMed ID: 32518058
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
    ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
    Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of immunosuppression on mortality in critically ill COVID-19 patients.
    Mirouse A; Darmon M; Zafrani L; Lengliné E; Azoulay E
    Br J Haematol; 2020 Nov; 191(3):394-395. PubMed ID: 33103761
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of MS disease-modifying therapies on responses to vaccinations: A review.
    Ciotti JR; Valtcheva MV; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102439. PubMed ID: 32769063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 in MS: Initial observations from the Pacific Northwest.
    Bowen JD; Brink J; Brown TR; Lucassen EB; Smoot K; Wundes A; Repovic P
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32457226
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
    Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
    Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
    Fernández-Díaz E; Gracia-Gil J; García-García JG; Palao M; Romero-Sánchez CM; Segura T
    Mult Scler Relat Disord; 2020 Oct; 45():102402. PubMed ID: 32711297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.